Share on StockTwits

Investment analysts at Guggenheim boosted their price target on shares of Gilead Sciences (NASDAQ:GILD) from $104.00 to $113.00 in a note issued to investors on Wednesday, American Banking & Market News reports. Guggenheim’s target price points to a potential upside of 55.09% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Deutsche Bank raised their price target on shares of Gilead Sciences from $132.00 to $135.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Gilead Sciences from $85.00 to $82.00 in a research note on Tuesday. They now have a “hold” rating on the stock. Finally, analysts at Wells Fargo & Co. reiterated a “buy” rating on shares of Gilead Sciences in a research note on Monday, April 14th. They now have a $5.79 price target on the stock. Four analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $88.26.

Gilead Sciences (NASDAQ:GILD) traded up 2.83% during mid-day trading on Wednesday, hitting $74.92. 14,284,930 shares of the company’s stock traded hands. Gilead Sciences has a 52-week low of $46.70 and a 52-week high of $84.88. The stock has a 50-day moving average of $73.9 and a 200-day moving average of $73.7. The company has a market cap of $115.2 billion and a P/E ratio of 40.25.

Gilead Sciences (NASDAQ:GILD) last released its earnings data on Tuesday, April 22nd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up 97.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $4.21 EPS for the current fiscal year.

In other Gilead Sciences news, EVP Norbert Bischofberger unloaded 90,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $67.03, for a total transaction of $6,032,700.00. Following the completion of the sale, the executive vice president now directly owns 119,302 shares in the company, valued at approximately $7,996,813. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.